Skip to navigation Skip to content

COVID-19 Vaccine Guidance for People Living with MS


In this article

Guidance on the Use of Evusheld in MS

Last updated: December 17, 2021

The U.S. Food and Drug Administration (FDA) has authorized Evusheld as a medication to prevent COVID-19 in some individuals age of 12 years and older. This prevention medication is strictly for those who are not expected to have adequate immune responses to the vaccine or who have a severe allergy to the vaccine.

Evusheld is not a substitute for vaccination against COVID-19. View Evusheld guidance.

Last updated: December 22, 2021
Información disponible en español.

Vaccination against COVID-19 is critical for public safety and, especially, the safety of the most vulnerable among us. We encourage you to get vaccinated as soon as possible. Please review the full guidance below.

Learn more about the COVID-19 vaccine:

COVID-19 vaccine guidance for people living with MS

People living with multiple sclerosis (MS) are seeking peace of mind on the safety and effectiveness of the COVID-19 vaccines. In response, the Society convened a group of expert researchers and medical professionals to review the available science and make fact-based recommendations.

While research is underway to learn more about the specific experience of people with MS receiving a COVID-19 vaccination, data on the safety and effectiveness of COVID-19 vaccines in those with MS are limited. Our guidance is based on clinical trials of the general population and studies of other vaccines administered to people with MS. Our guidance will be updated as more is learned from scientific studies of the vaccines.

This guidance applies to people with MS ages 12 and older and only for the vaccines authorized or approved for use for their age in the United States, Pfizer BioNTech (Comirnaty), Moderna and Janssen/J&J.

People with MS should be vaccinated against COVID-19

The science has shown us that the COVID-19 vaccines are safe and effective. Like other medical decisions, the decision to get a vaccine is best made in partnership with your healthcare provider. Most people with relapsing and progressive forms of MS should be vaccinated. The risks of COVID-19 outweigh any potential risks from the vaccine. In addition, members of the same household and close contacts should also be vaccinated against COVID-19 when available to decrease the impact of the virus.

People with progressive MS, those who are older, those who have a higher level of physical disability, those with certain medical conditions (e.g., diabetes, high blood pressure, obesity, heart and lung disease, pregnancy), and Black and Hispanic populations are among groups with the highest risk for hospitalization due to COVID-19. Individuals in these high-risk groups are especially encouraged to get vaccinated.

If you’ve had COVID-19 and recovered, you should also get the vaccine. We don’t know how well protected people are after COVID-19 infection, or how long this protection might last. People who have had COVID-19 infection in the past can get infected again. . Even if you have been vaccinated you may need an additional dose or booster.

COVID-19 vaccines are safe for people with MS

None of the available vaccines contain live virus and the vaccines will not cause COVID-19. The vaccines are not likely to trigger an MS relapse or have any impact on long-term disease progression. The risk of getting COVID-19 far outweighs any risk of having an MS relapse from the vaccine. Learn more about how mRNA vaccines (Pfizer and Moderna) and vector vaccines (J&J) work from the Centers for Disease Control and Prevention (CDC).
Any vaccine can cause side effects, including a fever. A fever can make your MS symptoms worse temporarily, but they should return to prior levels after the fever is gone. Even if you have side effects, it’s important to get the second dose of the vaccine for it to be effective.

COVID-19 vaccines are safe to use with MS medications

Continue your disease modifying therapy (DMT) unless you are advised by your MS healthcare provider to stop or delay it. Stopping some DMTs abruptly can cause severe increase in disability with new lesions on MRI. Based on data from previous studies of other vaccines and DMTs, getting the COVID-19 vaccine while on any DMT is safe. Some DMTs may make the vaccine less effective but it will still provide some protection. For those taking Kesimpta, Lemtrada, Ocrevus, or Rituxan—you may consider coordinating the timing of your vaccine with the timing of your DMT dose. Work with your MS healthcare provider to determine the best schedule for you. Review our considerations of timing MS medications with these vaccines.

Preferred COVID-19 vaccines for those living with MS

Any of the three vaccines approved or authorized for your age are safe for people living with MS. However, the CDC now recommends the mRNA vaccines over the J & J vaccine. People with MS should select the Pfizer or Moderna vaccine when getting vaccinated.

Staying safe following COVID-19 vaccination

The authorization of safe and effective vaccines for COVID-19 brings us one step closer to eliminating this pandemic. Whether you receive the Pfizer, Moderna or J&J vaccine, it takes two weeks after being fully vaccinated before you are considered protected.

In addition to getting vaccinated, science shows that wearing a face mask, social distancing and washing your hands are the best ways to slow the spread of the virus. View CDC information on how to protect yourself and others even when you’ve been fully vaccinated. For people with MS, especially those in high-risk groups and those taking a DMT that might reduce the effectiveness of the vaccines, the safest approach is to continue wearing masks, practicing social distancing, and performing regular handwashing.

COVID-19 vaccines are safe to get at the same time as other vaccines

The CDC has determined it is safe for you to get the flu vaccine and other vaccines at the same time as the COVID-19 vaccine.
Learn more about the safe and effective COVID-19 vaccines from the Centers for Disease Control and Prevention.

Experts consulted in the development of this guidance

The National MS Society consulted the following experts in the development of this guidance:

MS neurologists and experts

  • Nancy Sicotte, MD, FAAN—Chair, National MS Society’s National Medical Advisory Committee, Cedars-Sinai Medical Center, USA
  • Brenda Banwell, MD— Chair of MS International Federation International Medical and Scientific Advisory Board (IMSB) – University of Pennsylvania, USA
  • Amit Bar-Or, MD, FRCPC—President, International Society for Neuroimmunology - University of Pennsylvania, USA
  • Jorge Correale, MD-- Raul Carrea Institute for Neurological Research, FLENI, Buenos Aires, Argentina
  • Anne Cross, MD, FAAN—Washington University and Secretary of Board of Governors of the Consortium of MS Centers, USA
  • Jaime Imitola, MD, FAAN—University of Connecticut, UConn Health, USA
  • Dorlan Kimbrough, MD—Duke University, USA
  • Avindra Nath, MD—National Institutes of Health/National Institutes of Neurological Disorders and Stroke, USA
  • Scott Newsome, DO, MSCS, FAAN, FANA—Johns Hopkins University and President of the Board of Governors of the Consortium of MS Centers, USA
  • Penny Smyth, MD, FRCPC—University of Alberta, Canada
  • Rachael Stacom, MS, ANP-BC, MSCN—Independence Care System, USA

Staff from MS Partner Organizations

  • Julie Fiol, RN, MSCN—National MS Society, USA
  • Pamela Kanellis—MS Society of Canada
  • Julie Kelndorfer—MS Society of Canada
  • Hope Nearhood, MPH, PMP—National MS Society, USA
  • Leslie Ritter—National MS Society, USA

This guidance is endorsed by the Consortium of MS Centers, the MS Coalition and other organizations:

Additional Resources



En Español

Estamos observando de cerca la situación del coronavirus (COVID-19) y tomando decisiones sobre la mejor manera de actuar en esta situación sin precedente.

Aprende Más

Aprende Más

The National MS Society is Here to Help

Need More Information?

We Are Here

Our MS Navigators help identify solutions and provide access to the resources you are looking for. Call 1-800-344-4867 or contact us online.

Contact Us

Contact Us

Weekly Webinars

The Ask an MS Expert weekly webinar series is an opportunity to learn more about multiple sclerosis from top MS experts.

Learn More

Learn More

© 2022 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.